First human doses of experimental drug ARO-033 begin safety testing
NCT ID NCT07662096
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study is the first time the experimental drug ARO-033 is being given to humans. Its main goal is to check the safety and tolerability of single and multiple doses in healthy adult volunteers. Researchers will also measure how the drug moves through the body. This is an early step to see if ARO-033 is safe enough for future studies in people with specific diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARO-033
- What this could lead to
- If safe and well-tolerated, this could pave the way for future studies of ARO-033 in specific diseases.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only tests safety and drug levels, not whether the drug works for any condition. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site 1
RECRUITINGAuckland, 1010, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates